Congenital Hyperinsulinism International
Congenital Hyperinsulinism International shows consistent revenue growth and strong asset accumulation over the past decade.
EIN: 203068945 · Glen Ridge, NJ · NTEE: G12 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $1.3M |
| Total Expenses | $1.0M |
| Program Spending | 85% |
| CEO/Top Officer Pay | $1.15M |
| Net Assets | $1.7M |
| Transparency Score | 90/100 |
Is Congenital Hyperinsulinism International Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Congenital Hyperinsulinism International directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Congenital Hyperinsulinism International
Congenital Hyperinsulinism International (EIN: 203068945) is a nonprofit organization based in Glen Ridge, NJ, classified under NTEE code G12. The organization reported total revenue of $1.3M and total assets of $2.2M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Congenital Hyperinsulinism International's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Congenital Hyperinsulinism International is a mid-size nonprofit that has been operating for 20 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 31.4%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $1.2M |
| Total Expenses | $1.0M |
| Surplus / Deficit | +$107K |
| Total Assets | $1.8M |
| Total Liabilities | $99K |
| Net Assets | $1.7M |
| Operating Margin | 9.3% |
| Debt-to-Asset Ratio | 5.5% |
| Months of Reserves | 20.7 months |
Financial Health Grade: A
In 2023, Congenital Hyperinsulinism International reported a surplus of $107K with revenue exceeding expenses, holds 20.7 months of operating reserves (strong position), has a debt-to-asset ratio of 5.5% (very low leverage).
Financial Trends
Over 13 years of filings (2011–2023), Congenital Hyperinsulinism International's revenue has grown at a compound annual growth rate (CAGR) of 31.4%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -8.9% | +25.1% | +9.7% |
| 2022 | +42.1% | +53.9% | +39.6% |
| 2021 | +25.5% | +15.9% | +7.3% |
| 2020 | +51.7% | -5.4% | +85.0% |
| 2019 | +31.2% | +29.4% | -4.1% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2006 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Congenital Hyperinsulinism International with a Mission Score of 90 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Congenital Hyperinsulinism International allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $107K, with revenue exceeding expenses.
- Debt-to-asset ratio: 5.5%.
Executive Compensation Analysis
The organization reports 0% officer compensation across all available filings, indicating that its leadership is either unpaid or compensated through other means not categorized as officer compensation, which is unusual for an organization of its size ($1.15M revenue in 2023) and could suggest a highly volunteer-driven model or a lack of transparency in reporting executive pay.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Congenital Hyperinsulinism International's IRS 990 filings:
- 0% officer compensation reported across all filings, which is unusual for an organization of this size and could indicate uncompensated leadership or alternative compensation structures not clearly disclosed as officer pay.
Strengths
The following positive indicators were identified for Congenital Hyperinsulinism International:
- Consistent and significant revenue growth over a decade, from $217,087 in 2014 to $1,150,291 in 2023.
- Strong asset accumulation, growing from $254,302 in 2014 to $1,803,323 in 2023.
- Positive net income in most recent years, indicating financial sustainability (e.g., $106,845 in 2023, $428,570 in 2022).
- Low liabilities relative to assets, suggesting good financial health and minimal debt burden (e.g., $98,789 liabilities vs. $1,803,323 assets in 2023).
- Extensive filing history (13 filings) demonstrating transparency and consistent reporting.
Frequently Asked Questions about Congenital Hyperinsulinism International
Is Congenital Hyperinsulinism International a legitimate charity?
Congenital Hyperinsulinism International (EIN: 203068945) is a registered tax-exempt nonprofit based in New Jersey. Our AI analysis gives it a Mission Score of 90/100. It has 13 years of IRS 990 filings on record. Total revenue: $1.3M. 1 red flag identified. 5 strengths noted. Financial health grade: A.
How does Congenital Hyperinsulinism International spend its money?
Congenital Hyperinsulinism International directs 85% of its spending to programs and services. Fundraising costs 5%. This exceeds the 65% industry benchmark.
Are donations to Congenital Hyperinsulinism International tax-deductible?
Congenital Hyperinsulinism International is registered as a tax-exempt nonprofit (EIN: 203068945). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How much does the Congenital Hyperinsulinism International CEO make?
Congenital Hyperinsulinism International's highest-compensated officer earns $1.15M annually. The organization reported $1.3M in total revenue. Executive compensation data is disclosed in IRS 990 filings.
What percentage of Congenital Hyperinsulinism International's spending goes to programs?
Congenital Hyperinsulinism International directs 85% to programs, 5% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Congenital Hyperinsulinism International compare to similar nonprofits?
With a transparency score of 90/100 (Excellent), Congenital Hyperinsulinism International is above average for NTEE category G12 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Congenital Hyperinsulinism International located?
Congenital Hyperinsulinism International is headquartered in Glen Ridge, New Jersey and files with the IRS under EIN 203068945. It is classified under NTEE code G12.
How many years of IRS 990 filings does Congenital Hyperinsulinism International have?
Congenital Hyperinsulinism International has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $1.3M in total revenue.
Is Congenital Hyperinsulinism International a good charity?
Based on its financial data, Congenital Hyperinsulinism International appears to be a good charity. It demonstrates strong financial growth, responsible asset management, and a consistent surplus of revenue over expenses. The absence of reported officer compensation suggests a high dedication to its mission, though further inquiry into how leadership is supported might be warranted.
How has the organization's revenue grown over time?
The organization has experienced significant revenue growth, increasing from $217,087 in 2014 to $1,150,291 in 2023, representing a more than five-fold increase over a decade.
What is the organization's asset growth trend?
Assets have consistently grown, from $254,302 in 2014 to $1,803,323 in 2023, indicating effective financial management and accumulation of resources.
Filing History
IRS 990 filing history for Congenital Hyperinsulinism International showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Congenital Hyperinsulinism International's revenue has grown by 2541.1%, moving from $44K to $1.2M. Total assets increased by 2325.4% over the same period, from $74K to $1.8M. Total functional expenses rose by 2481.8%, from $40K to $1.0M. In its most recent filing year (2023), Congenital Hyperinsulinism International reported a surplus of $107K, with revenue exceeding expenses. The organization holds $99K in liabilities against $1.8M in assets (debt-to-asset ratio: 5.5%), resulting in net assets of $1.7M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $1.2M | $1.0M | $1.8M | $99K | — | — |
| 2022 | $1.3M | $834K | $1.6M | $47K | — | View 990 |
| 2021 | $888K | $542K | $1.2M | $9K | — | View 990 |
| 2020 | $708K | $468K | $1.1M | $275K | — | View 990 |
| 2019 | $467K | $495K | $593K | $11K | — | View 990 |
| 2018 | $356K | $382K | $618K | $8K | — | View 990 |
| 2017 | $472K | $280K | $653K | $17K | — | View 990 |
| 2016 | $306K | $205K | $446K | $0 | — | View 990 |
| 2015 | $220K | $130K | $344K | $0 | — | View 990 |
| 2014 | $217K | $93K | $254K | $37 | — | View 990 |
| 2013 | $112K | $77K | $130K | $0 | — | View 990 |
| 2012 | $70K | $50K | $95K | $0 | — | View 990 |
| 2011 | $44K | $40K | $74K | $0 | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $1.2M, expenses of $1.0M, and assets of $1.8M (revenue -8.9% year-over-year).
- 2022: Revenue of $1.3M, expenses of $834K, and assets of $1.6M (revenue +42.1% year-over-year).
- 2021: Revenue of $888K, expenses of $542K, and assets of $1.2M (revenue +25.5% year-over-year).
- 2020: Revenue of $708K, expenses of $468K, and assets of $1.1M (revenue +51.7% year-over-year).
- 2019: Revenue of $467K, expenses of $495K, and assets of $593K (revenue +31.2% year-over-year).
- 2018: Revenue of $356K, expenses of $382K, and assets of $618K (revenue -24.6% year-over-year).
- 2017: Revenue of $472K, expenses of $280K, and assets of $653K (revenue +54.1% year-over-year).
- 2016: Revenue of $306K, expenses of $205K, and assets of $446K (revenue +39.1% year-over-year).
- 2015: Revenue of $220K, expenses of $130K, and assets of $344K (revenue +1.3% year-over-year).
- 2014: Revenue of $217K, expenses of $93K, and assets of $254K (revenue +93.7% year-over-year).
- 2013: Revenue of $112K, expenses of $77K, and assets of $130K (revenue +61.3% year-over-year).
- 2012: Revenue of $70K, expenses of $50K, and assets of $95K (revenue +59.6% year-over-year).
- 2011: Revenue of $44K, expenses of $40K, and assets of $74K.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Congenital Hyperinsulinism International:
Data Sources and Methodology
This transparency report for Congenital Hyperinsulinism International is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.